GU Cancers 2020 | Immunotherapy with radiotherapy in RCC: is there a benefit?
Thanks for your feedback, this will help us improve our content for you!
Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the results of the RADVAX trial (NCT03065179) combining immune checkpoint inhibition with stereotactic radiation in metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up